Background/Aim: Uremic patients are at an increased risk of being affected by tuberculosis (TB). Periodical tuberculin skin tests were suggested to detect TB-infected patients. These were replaced by chest radiographs in endemic areas like Taiwan. However, almost 50% of the TB incidence in dialysis patients was extrapulmonary. In this study, we tried to investigate the value of tuberculin tests in dialysis patients in endemic areas. Methods: The patients were recruited from our dialysis unit. Purified protein derivative (PPD) and control tests with antigens for Candida and toxoid were performed using the Mantoux method. PPD with >10-mm induration will be considered positive. Skin anergy meant that the indurations of all antigens were less than 5 mm. A follow-up was done 12 months after the tests. Results: A total of 177 patients were evaluated. Anergy was found in 40 patients (22.6%). A positive predictor of anergy was age >45 years (p = 0.03), while a negative predictor was prealbumin >20 mg/dl (p = 0.04). Fifty-three patients (30%) had positive PPD tests. Seven of the positive PPD patients (13.2%) developed active TB during the following years. Among the 40 patients with skin anergy, 6 (15%) were found to have active TB. Of the 48 patients (21.1%) with indurations of the PPD tests between 5 and 10 mm, none was found to have active TB. Conclusion: Although anergy will influence the sensitivity of PPD tests, these tests in combination with anergy tests could help to establish the diagnosis of TB in uremic patients, even in TB-endemic areas.

Keywords:
Tuberculin test, Skin anergy, Dialysis patients, tuberculosis
1.
Lundin AP, Adler AJ, Berlyne GM, Friedman EA: Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 1979;67:597–602.
2.
Sasaki S, Akiba T, Suenaga M, Tomura S, Yoshiyama N, Nakagawa S, Shoji T, Sasaoka T, Takeuchi J: Ten years’ survey of dialysis-associated tuberculosis. Nephron 1979;24:141–145.
3.
Rutsky EA, Rostand SG: Mycobacteriosis in patients with chronic renal failure. Arch Intern Med 1980;140:57–61.
4.
Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH: Tuberculosis in patients with end-stage renal disease. Am J Med 1980;68:59–65.
5.
Mitwalli A: Tuberculosis in patients on maintenance dialysis. Am J Kidney Dis 1991;18:579–582.
6.
Touraine JL, Touraine F, Revillard JP, Brochier J, Traeger J: T-lymphocytes and serum inhibitors of cell-mediated immunity in renal insufficiency. Nephron 1975;14:195–208.
7.
Newberry WM, Sanford JP: Defective cellular immunity in renal failure: Depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. J Clin Invest 1971;50:1262–1271.
8.
Murthy BVR, Pereira BJG: A 1990s perspective of hepatitis C, human immunodeficiency virus, and tuberculosis infections in dialysis patients. Semin Nephrol 1997;17:346–363.
9.
Diego J, Lauber J, Fraser V: Tuberculosis in a chronic hemodialysis center (abstract). Infect Control Hosp Epidemiol 1995;16:36.
10.
Janis EM, Allen DW, Glesby MJ, Carey LA, Mundy LM, Gopalan R, Chaisson RE, Longcope Firm of the Osler Medical Housestaff: Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients. Am J Med 1996;100:186–192.
11.
Palmer DL, Reed WP: Delayed hypersensitivity skin testing. II. Clinical correlates and anergy. J Infect Dis 1974;130:138–143.
12.
Woeltje KF, Mathew A, Rothstein M, Seiler S, Fraser VJ: Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis 1998;31:848–852.
13.
Smirnoff M, Patt C, Seckler B, Adler JJ: Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 1998;113:25–27.
14.
Chou KJ, Fang HC, Bai KJ, Hwang SJ, Yang WC, Chung HM: Tuberculosis in maintenance dialysis patients. Nephron 2001;88:138–143.
15.
Cohen G, Haag-Weber, Hörl WH: Immune dysfunction in uremia. Kidney Int Suppl 1997;62:79–82.
16.
Bass JB: The tuberculin test; in Relchman LB, Hershfield ES (eds): Tuberculosis: A Comprehensive International Approach. New York, Dekker, 1993, pp 139–148.
17.
Landi S: Production and standardization of tuberculin; in Kubica GP, Wayne LG (eds): The mycobacteria: A Source Book. New York, Dekker, 1984, pp 505–535.
18.
Guld J, Bentzon MW, Blelker MA, Griep WA, Magriusan M, Wadler H: Standardization of a new batch of purified tuberculin (PPD) intended for international use. Bull World Health Organ 1958;19:845–951.
19.
Arnadottir T, Rieder HL, Trebucq A, Waaler HT: Guidelines for conducting tuberculin skin test surveys in high prevalence countries. Tuber Lung Dis 1996;77(suppl 1):1–19.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.